GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dendreon Corp (FRA:DNR) » Definitions » Cyclically Adjusted PB Ratio

Dendreon (FRA:DNR) Cyclically Adjusted PB Ratio : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Dendreon Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Dendreon Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Dendreon's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dendreon Cyclically Adjusted PB Ratio Chart

Dendreon Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dendreon Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Mar15
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dendreon's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Dendreon's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dendreon's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dendreon's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Dendreon's Cyclically Adjusted PB Ratio falls into.



Dendreon Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Dendreon's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2014 is calculated as:

For example, Dendreon's adjusted Book Value per Share data for the three months ended in Sep. 2014 was:

Adj_Book=Book Value per Share/CPI of Sep. 2014 (Change)*Current CPI (Sep. 2014)
=-1.565/100.4278*100.4278
=-1.565

Current CPI (Sep. 2014) = 100.4278.

Dendreon Quarterly Data

Book Value per Share CPI Adj_Book
200412 2.516 80.290 3.147
200503 2.312 81.555 2.847
200506 2.274 82.062 2.783
200509 1.985 83.876 2.377
200512 2.296 83.032 2.777
200603 1.696 84.298 2.021
200606 1.419 85.606 1.665
200609 1.128 85.606 1.323
200612 1.256 85.142 1.482
200703 0.894 86.640 1.036
200706 0.741 87.906 0.847
200709 0.560 87.964 0.639
200712 0.334 88.616 0.379
200803 0.175 90.090 0.195
200806 0.278 92.320 0.302
200809 0.103 92.307 0.112
200812 0.210 88.697 0.238
200903 0.107 89.744 0.120
200906 1.084 91.003 1.196
200909 0.719 91.120 0.792
200912 2.955 91.111 3.257
201003 2.155 91.821 2.357
201006 3.634 91.962 3.969
201009 2.892 92.162 3.151
201012 2.612 92.474 2.837
201103 2.580 94.283 2.748
201106 2.069 95.235 2.182
201109 1.500 95.727 1.574
201112 1.740 95.213 1.835
201203 1.374 96.783 1.426
201206 1.045 96.819 1.084
201209 0.291 97.633 0.299
201212 0.171 96.871 0.177
201303 -0.176 98.209 -0.180
201306 -0.482 98.518 -0.491
201309 -0.765 98.790 -0.778
201312 -1.129 98.326 -1.153
201403 -1.293 99.695 -1.303
201406 -1.378 100.560 -1.376
201409 -1.565 100.428 -1.565

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Dendreon  (FRA:DNR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Dendreon Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Dendreon's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dendreon (FRA:DNR) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Dendreon Corp is a Delaware corporation. The Company is a biotechnology company focused on the discovery, development and commercialization of novel therapeutics that improve cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. PROVENGE(r) (sipuleucel-T), is its first commercialized product licensed by the United States Food and Drug Administration, and is a first in class autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. Prostate cancer is the most common non-skin cancer among men in the United States, with over one million men currently diagnosed with the disease, and the second cause of cancer deaths in men in the United States. The Company owns worldwide rights for PROVENGE. The Other potential product candidates we have under development include our investigational active cellular immunotherapy, DN24-02, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu. In addition, the Company has developed an orally-available small molecule treatment targeting TRPM8 that could be applicable to multiple types of cancer. The Company currently depends on specialized vendor relationships that are not readily replaceable for some of the components for its active immunotherapy candidates. Products such as chemotherapeutics, androgen metabolism or androgen receptor antagonists, endothelin A receptor antagonists, antisense compounds, angiogenesis inhibitors and gene therapies for cancer are also under development by a number of companies and could potentially compete with PROVENGE and its other product candidates. The Company's competitors include major pharmaceutical companies. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials. The Company is also subject to regulation by the Occupational Safety and Health Administration ('OSHA'), and the Environmental Protection Agency ('EPA'), and to regulation under the Toxic Substances Control Act.

Dendreon (FRA:DNR) Headlines

No Headlines